Heterozygous Familial Hypercholesterolemia (HeFH) is a prevalent genetic disorder, which is typically characterized by markedly elevated levels of total cholesterol and low-density lipoprotein cholesterol (LDL-C), the presence of tendon xanthomas and corneal arcus, as well as an increased susceptibility to premature atherosclerotic cardiovascular diseases (ASCVD).Extensive research conducted both domestically and internationally has demonstrated that HeFH has a relatively high prevalence. Nevertheless, the awareness and implementation rates of its treatment modalities remain rather low. Currently, commonly adopted treatment strategies encompass lifestyle modifications, the use of statin medications, and PCSK9 inhibitors, among others. As the development of novel lipid-lowering drugs and innovative treatment approaches continues to progress, the range of available treatment options is becoming progressively more diverse. Extensive research conducted both domestically and internationally has demonstrated that HeFH has a relatively high prevalence. Nevertheless, the awareness and implementation rates of its treatment modalities are relatively low. Among the existing treatment regimens, lifestyle interventions, statin drugs, and PCSK9 inhibitors are commonly utilized. As the development of novel lipid-lowering drugs and innovative treatment approaches continues to progress, the range of available treatment options is becoming progressively more diverse. This review aims to explore the existing treatment modalities for heterozygous familial hypercholesterolemia as well as those that can be achieved in the future, with the intention of providing a comprehensive understanding and reference for relevant medical research and clinical practice.

Meilin Xiang, Shu Qin. Treatment Advances in Heterozygous Familial Hypercholesterolemia. International Journal of Frontiers in Medicine (2025), Vol. 7, Issue 1: 80-85. https://doi.org/10.25236/IJFM.2025.070113.

[1] ONORATO A, STURM A C. Heterozygous Familial Hypercholesterolemia [J]. Circulation, 2016, 133(14): e587-9.

[2] HU P, DHARMAYAT K I, STEVENS C A T, et al. Prevalence of Familial Hypercholesterolemia Among the General Population and Patients With Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analysis [J]. Circulation, 2020, 141(22): 1742-59.

[3] AIHAITI X, CHEN S, LI J, et al. Prevalence of familial hypercholesterolemia and its association with coronary artery disease: A Chinese cohort study [J]. Chronic Dis Transl Med, 2023, 9(2): 134-42.

[4] BRANDTS J, RAY K K. Familial Hypercholesterolemia: JACC Focus Seminar 4/4 [J]. J Am Coll Cardiol, 2021, 78(18): 1831-43.

[5] TADA H, OKADA H, NOHARA A, et al. Effect of Cumulative Exposure to Low-Density Lipoprotein-Cholesterol on Cardiovascular Events in Patients With Familial Hypercholesterolemia [J]. Circ J, 2021, 85(11): 2073-8.

[6] MCGOWAN M P, HOSSEINI DEHKORDI S H, MORIARTY P M, et al. Diagnosis and Treatment of Heterozygous Familial Hypercholesterolemia [J]. J Am Heart Assoc, 2019, 8(24): e013225.

[7] MACH F, BAIGENT C, CATAPANO A L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk [J]. Eur Heart J, 2020, 41(1): 111-88.

[8] ANTONIAZZI L, ARROYO-OLIVARES R, BITTENCOURT M S, et al. Adherence to a Mediterranean diet, dyslipidemia and inflammation in familial hypercholesterolemia [J]. Nutr Metab Cardiovasc Dis, 2021, 31(7): 2014-22.

[9] BARKAS F, NOMIKOS T, LIBEROPOULOS E, et al. Diet and Cardiovascular Disease Risk Among Individuals with Familial Hypercholesterolemia: Systematic Review and Meta-Analysis [J]. Nutrients, 2020, 12(8).

[10] PAQUETTE M, BERNARD S, CARIOU B, et al. Familial Hypercholesterolemia-Risk-Score: A New Score Predicting Cardiovascular Events and Cardiovascular Mortality in Familial Hypercholesterolemia [J]. Arterioscler Thromb Vasc Biol, 2021, 41(10): 2632-40.

[11] LEE S A, KIM W, HONG T J, et al. Effects of Fixed-dose Combination of Low-intensity Rosuvastatin and Ezetimibe Versus Moderate-intensity Rosuvastatin Monotherapy on Lipid Profiles in Patients With Hypercholesterolemia: A Randomized, Double-blind, Multicenter, Phase III Study [J]. Clin Ther, 2021, 43(9): 1573-89.

[12] BESSELING J, HOVINGH G K, HUIJGEN R, et al. Statins in Familial Hypercholesterolemia: Consequences for Coronary Artery Disease and All-Cause Mortality [J]. J Am Coll Cardiol, 2016, 68(3): 252-60.

[13] PANG J, CHAN D C, WATTS G F. The Knowns and Unknowns of Contemporary Statin Therapy for Familial Hypercholesterolemia [J]. Curr Atheroscler Rep, 2020, 22(11): 64.

[14] BOS S, DUVEKOT M H, TEN KATE G R, et al. Carotid artery plaques and intima medial thickness in familial hypercholesteraemic patients on long-term statin therapy: A case control study [J]. Atherosclerosis, 2017, 256: 62-6.

[15] VUORIO A, KUOPPALA J, KOVANEN P T, et al. Statins for children with familial hypercholesterolemia [J]. Cochrane Database Syst Rev, 2019, 2019(11).

[16] MACH F, RAY K K, WIKLUND O, et al. Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract [J]. Eur Heart J, 2018, 39(27): 2526-39.

[17] YAMASHITA S, MASUDA D, HARADA-SHIBA M, et al. Effectiveness and Safety of Lipid-Lowering Drug Treatments in Japanese Patients with Familial Hypercholesterolemia: Familial Hypercholesterolemia Expert Forum (FAME) Study [J]. J Atheroscler Thromb, 2022, 29(5): 608-38.

[18] HIRANO K, IKEGAMI C, TSUJII K, et al. Probucol enhances the expression of human hepatic scavenger receptor class B type I, possibly through a species-specific mechanism [J]. Arterioscler Thromb Vasc Biol, 2005, 25(11): 2422-7.

[19] YOKOTE K, AKO J, KITAGAWA K, et al. Safety and Effectiveness of Low-Density Lipoprotein Cholesterol-Lowering Therapy With Evolocumab for Familial Hypercholesterolemia/Hypercholesterolemia in Japan: A Real-World, Postmarketing, Single-Arm Study [J]. J Am Heart Assoc, 2024, 13(21): e035809.

[20] KASTELEIN J J, HOVINGH G K, LANGSLET G, et al. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia [J]. J Clin Lipidol, 2017, 11(1): 195-203.e4.

[21] BRANDTS J, DHARMAYAT K I, VALLEJO-VAZ A J, et al. A meta-analysis of medications directed against PCSK9 in familial hypercholesterolemia [J]. Atherosclerosis, 2021, 325: 46-56.

[22] PéREZ DE ISLA L, DíAZ-DíAZ J L, ROMERO M J, et al. Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients with Familial Hypercholesterolemia: The ARCHITECT Study [J]. Circulation, 2023, 147(19): 1436-43.

[23] SANTOS R D, WIEGMAN A, CAPRIO S, et al. Alirocumab in Pediatric Patients With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial [J]. JAMA Pediatr, 2024, 178(3): 283-93.

[24] RAY K K, WRIGHT R S, KALLEND D, et al. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol [J]. N Engl J Med, 2020, 382(16): 1507-19.

[25] RAAL F J, KALLEND D, RAY K K, et al. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia [J]. N Engl J Med, 2020, 382(16): 1520-30.

[26] WRIGHT R S, RAAL F J, KOENIG W, et al. Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial [J]. Cardiovasc Res, 2024, 120(12): 1400-10.

[27] WANG A, RICHHARIYA A, GANDRA S R, et al. Systematic Review of Low-Density Lipoprotein Cholesterol Apheresis for the Treatment of Familial Hypercholesterolemia [J]. J Am Heart Assoc, 2016, 5(7).

[28] VíšEK J, BLáHA M, BLáHA V, et al. Monitoring of up to 15 years effects of lipoprotein apheresis on lipids, biomarkers of inflammation, and soluble endoglin in familial hypercholesterolemia patients [J]. Orphanet J Rare Dis, 2021, 16(1): 110.

[29] HAJIGHASEMI S, MAHDAVI GORABI A, BIANCONI V, et al. A review of gene- and cell-based therapies for familial hypercholesterolemia [J]. Pharmacol Res, 2019, 143: 119-32.

[30] ZHAO H, LI Y, HE L, et al. In Vivo AAV-CRISPR/Cas9-Mediated Gene Editing Ameliorates Atherosclerosis in Familial Hypercholesterolemia [J]. Circulation, 2020, 141(1): 67-79.

[31] LI Z, ZHAO P, ZHANG Y, et al. Exosome-based Ldlr gene therapy for familial hypercholesterolemia in a mouse model [J]. Theragnostic, 2021, 11(6): 2953-65.

[32] YANG Z, JI P, LI Z, et al. Improved extracellular vesicle-based mRNA delivery for familial hypercholesterolemia treatment [J]. Theragnostic, 2023, 13(10): 3467-79.